Abstract 6002
Background
Although cancer patients are known to be at higher risk of infection and its subsequent complications, the magnitude of infection-related mortality in cancer patients remains unknown. In this study, data from Surveillance, Epidemiology, and End Results Program (SEER) were explored in order to identify how far infection was identified as the cause of death in cancer patients in the United States between 2010 and 2016.
Methods
Data were obtained using SEER*Stat version 8.3.5 where (SEER 18 Regs Nov 2018 Submission) was used as the data source. Only cases with malignant behavior, known age, and those in research database were included. Analysis was made for patients who were diagnosed between 2010 and 2016 whose vital status was reported as "dead" at the time of study cut-off. Data about cause of death were exported using case-listing session in SEER*Stat and were analyzed using SPSS version 25.
Results
1,012,769 cases were included in the final data analysis. Infection was identified as the cause of death in 1.89% of cases (n = 19,155). Infection-related mortality was much higher in patients diagnosed with hematological malignancies (3.6%, n = 3,472) compared with non-hematological malignant diseases (1.7%, n = 15683). Deaths related to infection were also higher in males (2.2%, n = 11,827) compared with females (1.6%, n = 7,328).
Conclusions
Although infection is perceived as a major cause of morbidity and mortality in cancer patients, its current magnitude may be lower than expectations. Infection-related mortality showed higher prevelance in males and in patients with hematological malignancies.
Clinical trial identification
N/A
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract